19 research outputs found
An Investigation of the Crystal Structure of dichloro-μ-tetra(n-butyrato)dirhenium(III)
No full textTitle: An Investigation of the Crystal Structure of dichloro-μ-tetra(n-butyrato)dirhenium(III), Author: Roderic J. Restivo, Location: ThodeDichloro-μ-tetra(n-butyrato)dirhenium(III) was examined by x-rays and found to consist of a centrosymmetric dimeric unit in an eclipsed rotomeric configuration with a short rhenium-rhenium bond length of 2.20(2)Å. A long rhenium-chlorine bond 2.53(1)Å is present in the molecular unit. The bonding in Re2(O2C.C3H7-N)4CL2 is discussed with reference to similar carboxylate dimer structures. A preliminary report on the structure of Re2(O4C.C3H7-N)2 is also presented.ThesisMaster of Science (MS
Three Approaches to Psychoanalytic Psychotherapy in Aotearoa New Zealand
No full textThis paper discusses three styles of psychoanalytic psychotherapy commonly practiced in Aotearoa New Zealand. Judi Blumenfeld Hoadley writes on object relations, Gustavo Restivo on the Lacanian orientation, and Sarah Calvert on relational psychoanalysis and the relational movement. Each author discusses their specific orientation towards psychoanalytic psychotherapy in terms of the historical origins, seminal theorists, and philosophical views. They also articulate the key theoretical concepts, clinical techniques, and unique links to the therapeutic relationship. Finally, the authors point out the specific organisations, training, and conferences available in Aotearoa New Zealand
Spine growth in the anterior cingulate cortex is necessary for the consolidation of contextual fear memory
No full textRemodeling of cortical connectivity is thought to allow initially hippocampus-dependent memories to be expressed independently of the hippocampus at remote time points. Consistent with this, consolidation of a contextual fear memory is associated with dendritic spine growth in neurons of the anterior cingulate cortex (aCC). To directly test whether such cortical structural remodeling is necessary for memory consolidation, we disrupted spine growth in the aCC at different times following contextual fear conditioning in mice. We took advantage of previous studies showing that the transcription factor myocyte enhancer factor 2 (MEF2) negatively regulates spinogenesis both in vitro and in vivo. We found that increasing MEF2-dependent transcription in the aCC during a critical posttraining window (but not at later time points) blocked both the consolidation-associated dendritic spine growth and subsequent memory expression. Together, these data strengthen the causal link between cortical structural remodeling and memory consolidation and, further, identify MEF2 as a key regulator of these processes.</jats:p
ChemInform Abstract: CRYSTAL AND MOLECULAR STRUCTURE OF ENDO,ENDO‐2,6‐BIS(PHENYLCARBAMOYLOXY)‐CIS‐BICYCLO(3.3.0)OCTANE
No full text
Metal-olefin complexes: Synthesis and molecular structure of trans-chloro(ethylene)bis(triphenylphosphine)iridium(I), IrCI(C2H4)(PPh3)2
No full textStructural studies of steric effects in phosphine complexes. Synthesis and crystal and molecular structure of the dinitrato(tricyclohexylphosphine)mercury(II) dimer
No full textA note on the multiplicative group of a division ring
No full textFor any group G its FC-centre may be defined as the subset of all elements having only finitely many conjugates. This is a subgroup and it allows one to define the upper central FC-series {Fn} by F0=1, F1=FC(G) and Fn+1/Fn=FC(G/Fn). If Fn=G for some n, then G is said to be FC-nilpotent. The author shows that if D is a division ring with centre Z and x∈D has infinitely many conjugates, then so does its image xZ× in D×/Z×, where D× is the multiplicative group of D. He deduces that any division ring D whose group D× is FC-nilpotent is commutative, thus generalizing a theorem which asserts commutativity when D× is nilpotent [L.-K. Hua, Acad. Sinica Science Record 3 (1950), 1--6; MR0039707 (12,584e)]. It follows that D is commutative whenever D× has the permutation property Pn defined by A. Restivo and C. Reutenauer [J. Algebra 89 (1984), no. 1, 102--104; MR0748230 (85k:20188)]
Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: A closer look at the role of siderosis
No full textPatients with thalassemia are often exposed to several risk factors for developing hepatocellular carcinoma (HCC) due to their repeated transfusions. However, even transfusion-independent patients with thalassemia intermedia (TI) can develop HCC, which is mainly attributed to a state of iron overload. We report here two cases and review the literature for the association between TI and HCC. Along with our cases, a total of 36 cases of HCC in thalassemic patients were reported in the literature. Of these, 22 (61percent) were TI patients with 6 (27percent) of them being hepatitis B and C negative. There was no consistency in their characteristics; therefore, we recommended screening thresholds for HCC in TI patients based on their total liver iron concentration (LIC).Borgna-Pignatti C, 2004, BRIT J HAEMATOL, V124, P114, DOI 10.1046-j.1365-2141.2003.04732.x; BRADBEAR RA, 1985, J NATL CANCER I, V75, P81; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002-hep.24199; Chung HY, 2003, HEPATOL RES, V26, P254, DOI 10.1016-S1386-6346(03)00109-8; Fleming RE, 2002, ANNU REV PHYSIOL, V64, P663, DOI 10.1146-annurev.physiol.64.081501.155838; HERRINTON LJ, 1995, AM J EPIDEMIOL, V142, P692; Ioannou GN, 2003, CLIN GASTROENTEROL H, V1, P246, DOI 10.1016-S1542-3565(03)00126-5; Kowdley KV, 2004, GASTROENTEROLOGY, V127, pS79, DOI 10.1016-j.gastro.2004.09.019; Mancuso A, 2006, HEMOGLOBIN, V30, P119, DOI 10.1080-03630260500455565; Mancuso A, 2005, AM J HEMATOL, V78, P158, DOI 10.1002-ajh.20289; Mancuso A, 2010, WORLD J HEPATOL, P171; Moyo VM, 1998, EUR J HAEMATOL, V60, P28; Musallam KM, 2011, HAEMATOL-HEMATOL J, V96, P1605, DOI 10.3324-haematol.2011.047852; Origa R, 2007, HAEMATOL-HEMATOL J, V92, P583, DOI 10.3324-haematol.10842; Pietrangelo A, 2007, HEPATOLOGY, V46, P1291, DOI 10.1002-hep.21886; Restivo Pantalone G, 2010, BRIT J HAEMATOL, P245; STEVENS RG, 1988, NEW ENGL J MED, V319, P1047, DOI 10.1056-NEJM198810203191603; Taher A, 2008, HAEMATOL-HEMATOL J, V93, P1584, DOI 10.3324-haematol.13098; Taher A, 2009, BRIT J HAEMATOL, V146, P569, DOI 10.1111-j.1365-2141.2009.07810.x; Taher A, 2009, BRIT J HAEMATOL, V147, P634, DOI 10.1111-j.1365-2141.2009.07848.x; Taher AT, 2011, BRIT J HAEMATOL, V152, P512, DOI 10.1111-j.1365-2141.2010.08486.x; TURLIN B, 1995, HEPATOLOGY, V22, P446, DOI 10.1016-0270-9139(95)90564-27111
Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: A closer look at the role of siderosis
No full textPatients with thalassemia are often exposed to several risk factors for developing hepatocellular carcinoma (HCC) due to their repeated transfusions. However, even transfusion-independent patients with thalassemia intermedia (TI) can develop HCC, which is mainly attributed to a state of iron overload. We report here two cases and review the literature for the association between TI and HCC. Along with our cases, a total of 36 cases of HCC in thalassemic patients were reported in the literature. Of these, 22 (61percent) were TI patients with 6 (27percent) of them being hepatitis B and C negative. There was no consistency in their characteristics; therefore, we recommended screening thresholds for HCC in TI patients based on their total liver iron concentration (LIC).Borgna-Pignatti C, 2004, BRIT J HAEMATOL, V124, P114, DOI 10.1046-j.1365-2141.2003.04732.x; BRADBEAR RA, 1985, J NATL CANCER I, V75, P81; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002-hep.24199; Chung HY, 2003, HEPATOL RES, V26, P254, DOI 10.1016-S1386-6346(03)00109-8; Fleming RE, 2002, ANNU REV PHYSIOL, V64, P663, DOI 10.1146-annurev.physiol.64.081501.155838; HERRINTON LJ, 1995, AM J EPIDEMIOL, V142, P692; Ioannou GN, 2003, CLIN GASTROENTEROL H, V1, P246, DOI 10.1016-S1542-3565(03)00126-5; Kowdley KV, 2004, GASTROENTEROLOGY, V127, pS79, DOI 10.1016-j.gastro.2004.09.019; Mancuso A, 2006, HEMOGLOBIN, V30, P119, DOI 10.1080-03630260500455565; Mancuso A, 2005, AM J HEMATOL, V78, P158, DOI 10.1002-ajh.20289; Mancuso A, 2010, WORLD J HEPATOL, P171; Moyo VM, 1998, EUR J HAEMATOL, V60, P28; Musallam KM, 2011, HAEMATOL-HEMATOL J, V96, P1605, DOI 10.3324-haematol.2011.047852; Origa R, 2007, HAEMATOL-HEMATOL J, V92, P583, DOI 10.3324-haematol.10842; Pietrangelo A, 2007, HEPATOLOGY, V46, P1291, DOI 10.1002-hep.21886; Restivo Pantalone G, 2010, BRIT J HAEMATOL, P245; STEVENS RG, 1988, NEW ENGL J MED, V319, P1047, DOI 10.1056-NEJM198810203191603; Taher A, 2008, HAEMATOL-HEMATOL J, V93, P1584, DOI 10.3324-haematol.13098; Taher A, 2009, BRIT J HAEMATOL, V146, P569, DOI 10.1111-j.1365-2141.2009.07810.x; Taher A, 2009, BRIT J HAEMATOL, V147, P634, DOI 10.1111-j.1365-2141.2009.07848.x; Taher AT, 2011, BRIT J HAEMATOL, V152, P512, DOI 10.1111-j.1365-2141.2010.08486.x; TURLIN B, 1995, HEPATOLOGY, V22, P446, DOI 10.1016-0270-9139(95)90564-27111
